BTIG lowered the firm’s price target on LifeMD to $12 from $14 and keeps a Buy rating on the shares after its Q2 results. The company’s EBITDA guidance for the year was reduced due to the Software business, but the firm is positive on the healthcare business having turned earnings positive, and there appears to be no slow-down in demand for weight management services, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- LifeMD to Report Second Quarter 2024 Financial Results on August 7
- LifeMD price target lowered to $10 from $12 at KeyBanc
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
- LifeMD launches private health insurance acceptance for primary care services
- LifeMD to Participate in the Truist Securities Healthcare Disruptors & Digital Health Summit
Questions or Comments about the article? Write to editor@tipranks.com